Potential therapeutic effects of mepacrine against clostridium perfringens enterotoxin in a mouse model of enterotoxemia

Mauricio A. Navarro, Archana Shrestha, John C. Freedman, Juliann Beingesser, Bruce A. McClane, Francisco A. Uzal

Research output: Contribution to journalArticle

Abstract

Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin that causes the symptoms of common bacterial food poisoning and several non-foodborne human gastrointestinal diseases, including antibiotic-associated diarrhea and sporadic diarrhea. In some cases, CPE-mediated disease can be very severe or fatal due to the involvement of enterotoxemia. Therefore, the development of potential therapeutics against CPE action during enterotoxemia is warranted. Mepacrine, an acridine derivative drug with broad-spectrum effects on pores and channels in mammalian membranes, has been used to treat protozoal intestinal infections in human patients. A previous study showed that the presence of mepacrine inhibits CPE-induced pore formation and activity in enterocyte-like Caco-2 cells, reducing the cytotoxicity caused by this toxin in vitro. Whether mepacrine is similarly protective against CPE action in vivo has not been tested. When the current study evaluated whether mepacrine protects against CPE-induced death and intestinal damage using a murine ligated intestinal loop model, mepacrine protected mice from the enterotoxemic lethality caused by CPE. This protection was accompanied by a reduction in the severity of intestinal lesions induced by the toxin. Mepacrine did not reduce CPE pore formation in the intestine but inhibited absorption of the toxin into the blood of some mice. Protection from enterotoxemic death correlated with the ability of this drug to reduce CPE-induced hyperpotassemia. These in vivo findings, coupled with previous in vitro studies, support mepacrine as a potential therapeutic against CPE-mediated enterotoxemic disease.

Original languageEnglish (US)
Article numbere00670
JournalInfection and Immunity
Volume87
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Enterotoxemia
Quinacrine
Therapeutic Uses
Diarrhea
Clostridium enterotoxin
Acridines
Hyperkalemia
Foodborne Diseases
Caco-2 Cells
Enterocytes
Gastrointestinal Diseases
Pharmaceutical Preparations
Intestines

Keywords

  • Clostridium perfringens
  • Enterotoxemia
  • Enterotoxin
  • Mepacrine

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Infectious Diseases

Cite this

Potential therapeutic effects of mepacrine against clostridium perfringens enterotoxin in a mouse model of enterotoxemia. / Navarro, Mauricio A.; Shrestha, Archana; Freedman, John C.; Beingesser, Juliann; McClane, Bruce A.; Uzal, Francisco A.

In: Infection and Immunity, Vol. 87, No. 4, e00670, 01.04.2019.

Research output: Contribution to journalArticle

Navarro, Mauricio A. ; Shrestha, Archana ; Freedman, John C. ; Beingesser, Juliann ; McClane, Bruce A. ; Uzal, Francisco A. / Potential therapeutic effects of mepacrine against clostridium perfringens enterotoxin in a mouse model of enterotoxemia. In: Infection and Immunity. 2019 ; Vol. 87, No. 4.
@article{fd8e61209d8148688cb949c1c2c3d74e,
title = "Potential therapeutic effects of mepacrine against clostridium perfringens enterotoxin in a mouse model of enterotoxemia",
abstract = "Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin that causes the symptoms of common bacterial food poisoning and several non-foodborne human gastrointestinal diseases, including antibiotic-associated diarrhea and sporadic diarrhea. In some cases, CPE-mediated disease can be very severe or fatal due to the involvement of enterotoxemia. Therefore, the development of potential therapeutics against CPE action during enterotoxemia is warranted. Mepacrine, an acridine derivative drug with broad-spectrum effects on pores and channels in mammalian membranes, has been used to treat protozoal intestinal infections in human patients. A previous study showed that the presence of mepacrine inhibits CPE-induced pore formation and activity in enterocyte-like Caco-2 cells, reducing the cytotoxicity caused by this toxin in vitro. Whether mepacrine is similarly protective against CPE action in vivo has not been tested. When the current study evaluated whether mepacrine protects against CPE-induced death and intestinal damage using a murine ligated intestinal loop model, mepacrine protected mice from the enterotoxemic lethality caused by CPE. This protection was accompanied by a reduction in the severity of intestinal lesions induced by the toxin. Mepacrine did not reduce CPE pore formation in the intestine but inhibited absorption of the toxin into the blood of some mice. Protection from enterotoxemic death correlated with the ability of this drug to reduce CPE-induced hyperpotassemia. These in vivo findings, coupled with previous in vitro studies, support mepacrine as a potential therapeutic against CPE-mediated enterotoxemic disease.",
keywords = "Clostridium perfringens, Enterotoxemia, Enterotoxin, Mepacrine",
author = "Navarro, {Mauricio A.} and Archana Shrestha and Freedman, {John C.} and Juliann Beingesser and McClane, {Bruce A.} and Uzal, {Francisco A.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1128/IAI.00670-18",
language = "English (US)",
volume = "87",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Potential therapeutic effects of mepacrine against clostridium perfringens enterotoxin in a mouse model of enterotoxemia

AU - Navarro, Mauricio A.

AU - Shrestha, Archana

AU - Freedman, John C.

AU - Beingesser, Juliann

AU - McClane, Bruce A.

AU - Uzal, Francisco A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin that causes the symptoms of common bacterial food poisoning and several non-foodborne human gastrointestinal diseases, including antibiotic-associated diarrhea and sporadic diarrhea. In some cases, CPE-mediated disease can be very severe or fatal due to the involvement of enterotoxemia. Therefore, the development of potential therapeutics against CPE action during enterotoxemia is warranted. Mepacrine, an acridine derivative drug with broad-spectrum effects on pores and channels in mammalian membranes, has been used to treat protozoal intestinal infections in human patients. A previous study showed that the presence of mepacrine inhibits CPE-induced pore formation and activity in enterocyte-like Caco-2 cells, reducing the cytotoxicity caused by this toxin in vitro. Whether mepacrine is similarly protective against CPE action in vivo has not been tested. When the current study evaluated whether mepacrine protects against CPE-induced death and intestinal damage using a murine ligated intestinal loop model, mepacrine protected mice from the enterotoxemic lethality caused by CPE. This protection was accompanied by a reduction in the severity of intestinal lesions induced by the toxin. Mepacrine did not reduce CPE pore formation in the intestine but inhibited absorption of the toxin into the blood of some mice. Protection from enterotoxemic death correlated with the ability of this drug to reduce CPE-induced hyperpotassemia. These in vivo findings, coupled with previous in vitro studies, support mepacrine as a potential therapeutic against CPE-mediated enterotoxemic disease.

AB - Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin that causes the symptoms of common bacterial food poisoning and several non-foodborne human gastrointestinal diseases, including antibiotic-associated diarrhea and sporadic diarrhea. In some cases, CPE-mediated disease can be very severe or fatal due to the involvement of enterotoxemia. Therefore, the development of potential therapeutics against CPE action during enterotoxemia is warranted. Mepacrine, an acridine derivative drug with broad-spectrum effects on pores and channels in mammalian membranes, has been used to treat protozoal intestinal infections in human patients. A previous study showed that the presence of mepacrine inhibits CPE-induced pore formation and activity in enterocyte-like Caco-2 cells, reducing the cytotoxicity caused by this toxin in vitro. Whether mepacrine is similarly protective against CPE action in vivo has not been tested. When the current study evaluated whether mepacrine protects against CPE-induced death and intestinal damage using a murine ligated intestinal loop model, mepacrine protected mice from the enterotoxemic lethality caused by CPE. This protection was accompanied by a reduction in the severity of intestinal lesions induced by the toxin. Mepacrine did not reduce CPE pore formation in the intestine but inhibited absorption of the toxin into the blood of some mice. Protection from enterotoxemic death correlated with the ability of this drug to reduce CPE-induced hyperpotassemia. These in vivo findings, coupled with previous in vitro studies, support mepacrine as a potential therapeutic against CPE-mediated enterotoxemic disease.

KW - Clostridium perfringens

KW - Enterotoxemia

KW - Enterotoxin

KW - Mepacrine

UR - http://www.scopus.com/inward/record.url?scp=85063712161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063712161&partnerID=8YFLogxK

U2 - 10.1128/IAI.00670-18

DO - 10.1128/IAI.00670-18

M3 - Article

C2 - 30642896

AN - SCOPUS:85063712161

VL - 87

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 4

M1 - e00670

ER -